Targets for tumor growth inhibition

Abstract

The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.

1 . A method for treating a disease in a mammal associated with undesirable activity or expression of ICT1030 peptide, comprising applying a composition that interacts with the ICT1030 peptide or gene, wherein the composition is capable of enhancing expression or activity of the ICT1030 when introduced into a tissue of the mammal. 
     
     
         2 . The method according to  claim 1 , wherein the disease is cancer or a precancerous growth. 
     
     
         3 . The method according to  claim 1 , wherein the tissue is a breast tissue, a colon tissue, a prostate tissue, a skin tissue, a bone tissue, a parotid gland tissue, a pancreatic tissue, a kidney tissue, a uterine cervix tissue, a lymph node tissue, or an ovarian tissue. 
     
     
         4 . The method according to  claim 1  wherein the composition is a nucleic acid. 
     
     
         5 . The method according to  claim 4 , wherein the nucleic acid is a decoy molecule, a decoy DNA, a double stranded DNA, a single-stranded DNA, a complexed DNA, an encapsulated DNA, a viral. DNA, a plasmid DNA, a naked RNA, an encapsulated RNA, a viral RNA, a double stranded RNA, a molecule capable of enhancing expression of the target ICTE1030 gene, or combinations thereof. 
     
     
         6 . (canceled) 
     
     
         7 . The method according to  claim 4 , wherein the nucleic acid composition comprises a siRNA, an RNAi or an shRNA or a nucleic acid molecule capable of encoding a siRNA, an RNAi or an shRNA. 
     
     
         8 .- 12 . (canceled) 
     
     
         13 . The method of  claim 1 , wherein the target ICT1030 gene comprises a polynucleotide selected from the group consisting of: (a) a polynucleotide encoding the polypeptide set forth in SEQ ID NO: 2; (b) a polynucleotide set forth in SEQ ID NO: 1 or SEQ ID NO: 3; and (c) a polynucleotide having at least about 90% sequence identity to the polynucleotide of (a) or (b). 
     
     
         14 .- 27 . (canceled) 
     
     
         28 . The method of  claim 1  wherein the composition is an antibody specific for the ICT1030 polypeptide set forth in SEQ ID NO: 2 or a polypeptide having at least 90% sequence identity to the polypeptide of SEQ ID NO: 2. 
     
     
         29 .- 32 . (canceled) 
     
     
         33 . A method for treating a disease in a mammal associated with undesirable expression or activity of ICT1031, ICT1024, ICT 1025, or ICT1003 peptide, comprising applying a composition containing an inhibitor that interacts with the ICT1031 ICT1024, ICT 1025, or ICT1003 peptide or DNA or RNA, wherein the composition is capable of reducing expression or activity of the ICT1031, ICT1024, ICT 1025, or ICT1003 peptide when introduced into a tissue of the mammal. 
     
     
         34 . The method according to  claim 33 , wherein the disease is cancer or a precancerous growth. 
     
     
         35 . The method according to  claim 33 , wherein the tissue is a breast tissue, a colon tissue, a prostate tissue, a skin tissue, a bone tissue, a parotid gland tissue, a pancreatic tissue, a kidney tissue, a uterine cervix tissue, a lymph node tissue, or an ovarian tissue. 
     
     
         36 . The method according to  claim 33 , wherein the composition is nucleic acid. 
     
     
         37 . The method according to  claim 36 , wherein the inhibitor is a siRNA, an RNAi, a shRNA, an antisense RNA, an antisense DNA, a decoy molecule, a decoy DNA, a double stranded DNA, a single-stranded DNA, a complexed DNA, an encapsulated DNA, a viral DNA, a plasmid DNA, a naked RNA, an encapsulated RNA, a viral RNA, a double stranded RNA, a molecule capable of generating RNA interference, or combinations thereof. 
     
     
         38 .- 44 . (canceled) 
     
     
         45 . The method of  claim 33 , wherein the target ICT1031 gene comprises a polynucleotide selected from the group consisting of: (a) a polynucleotide encoding the polypeptide set forth in SEQ ID NO: 5; (b) a polynucleotide set forth in SEQ ID NO: 4; and (c) a polynucleotide having at least about 90% sequence identity to the poly-nucleotide of a) or b). 
     
     
         46 . (canceled) 
     
     
         47 . (canceled) 
     
     
         48 . The method of  claim 33 , wherein the target ICT1003 gene comprises a polynucleotide selected from the group consisting of: (a) a polynucleotide encoding the polypeptide set forth in SEQ ID NO: 7; (b) a polynucleotide set forth in SEQ ID NO: 6 or SEQ ID NO: 8; and (c) a polynucleotide having at least about 90% sequence identity to the polynucleotide of a) or b). 
     
     
         49 . (canceled) 
     
     
         50 . (canceled) 
     
     
         51 . The method of  claim 33 , wherein the target ICT1024 gene comprises a polynucleotide selected from the group consisting of: (a) a polynucleotide encoding the polypeptide set forth in SEQ ID NO: 37; (b) a polynucleotide set forth in SEQ ID NOs: 58, 60, 61, 62, 64, 66, 68 or 69; and (c) a polynucleotide having at least about 90% sequence identity to the polynucleotide of a) or b). 
     
     
         52 . (canceled) 
     
     
         53 . (canceled) 
     
     
         54 . The method of  claim 33 , wherein the target ICT1025 gene comprises a polynucleotide selected from the group consisting of: (a) a polynucleotide encoding the polypeptide set forth in SEQ ID NO: 71; (b) a polynucleotide set forth in SEQ ID NO: 70; and (c) a polynucleotide having at least about 90% sequence identity to the polynucleotide of a) or b). 
     
     
         55 . (canceled) 
     
     
         56 . (canceled) 
     
     
         57 . A method for inhibiting cancer or precancerous growth in a mammalian issue, comprising contacting the tissue with an inhibitor that interacts with a target ICT1031, ICT1024, ICT 1025, or ICT1003 DNA or RNA and thereby reduces target ICT1031, ICT1024, ICT 1025, or ICT1003 gene expression. 
     
     
         58 . (canceled) 
     
     
         59 . The method according to  claim 57 , wherein the inhibitor is a siRNA, an RNAi, a shRNA, an antisense RNA, an antisense DNA, a decoy molecule, a decoy DNA, a double stranded DNA, a single-stranded DNA, a complexed DNA, an encapsulated DNA, a viral DNA, a plasmid DNA, a naked RNA, an encapsulated RNA, a viral RNA, a double stranded RNA, a molecule capable of generating RNA interference, or combinations thereof. 
     
     
         60 .- 73 . (canceled) 
     
     
         74 . The method according to  claim 33 , wherein the inhibitor is an anti-ICT1003 antibody, an anti-ICT1031 antibody, an anti-ICT1024 antibody or an anti-ICT1025 antibody. 
     
     
         75 . An antibody that binds to and inhibits the activity of a protein selected from: ICT1003, ICT1031, ICT1024 and ICT1025.